Novartis AG

Novartis AG is a leading global pharmaceutical company dedicated to reimagining medicine through scientific innovation, advanced research, and cutting-edge technology. Established in 1996 through the merger of Ciba-Geigy and Sandoz, with corporate roots dating back more than a century, Novartis is headquartered in Basel, Switzerland. The company focuses on developing innovative prescription medicines that address serious diseases across oncology, cardiovascular medicine, neuroscience, immunology, renal diseases, and rare genetic disorders.

Novartis invests heavily in research and development, utilizing artificial intelligence, genomics, cell and gene therapy, radioligand therapy, and precision medicine to accelerate drug discovery and improve patient outcomes. Its global research organization collaborates with academic institutions, biotechnology companies, and healthcare providers to translate scientific discoveries into breakthrough therapies.

With operations in over 140 countries, Novartis maintains a world-class manufacturing and distribution network supported by strict quality systems and international regulatory compliance. The company is recognized for its commitment to sustainability, digital transformation, ethical business practices, and patient-centered innovation. Through continuous investment in advanced technologies and global healthcare partnerships, Novartis remains one of the world’s most influential pharmaceutical companies, delivering innovative medicines that improve and extend the lives of millions of patients worldwide.